New drug combo aimed at tough cancers pulled before starting
NCT ID NCT07328490
First seen Jan 11, 2026 · Last updated Jun 22, 2026 · Updated 24 times
Summary
This study planned to test a combination of two drugs—tarlatamab and sacituzumab govitecan—in adults with extensive-stage small cell lung cancer or extrapulmonary neuroendocrine cancer that had returned or not responded to prior treatment. The goal was to find a safe dose and see if the drugs could shrink tumors. However, the trial was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tarlatamab and sacituzumab govitecan
What this could lead to
If it works, this could point toward a new treatment option for aggressive lung and neuroendocrine cancers that have stopped responding to standard therapy.
What could go wrong
This trial was withdrawn before enrolling any participants, so no data on safety or effectiveness exist. The combination may cause significant side effects, and it is unknown if it will work better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.